| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.094 | 0.08 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.091 | 0.08 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.09 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | -0.08 | 0.09 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.09 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | 0.055 | 0.09 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.09 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.09 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.057 | 0.09 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.09 |